Cases & Deals

  • Home
  • Practices
  • Merck builds global patent portfolio related to small molecule inhibitors of cytochrome P450 11A1 (CYP11A1) for treatment of mCRPC

Share

Merck builds global patent portfolio related to small molecule inhibitors of cytochrome P450 11A1 (CYP11A1) for treatment of mCRPC

May 2026

Client(s) Merck & Co., Inc.

Jones Day is representing Merck & Co. in managing a global patent portfolio licensed from Orion Corporation related to inhibitors of cytochrome P450 11A1 (CYP11A1) for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.